MegaPro Biomedical Co Ltd

MegaPro Biomedical operates with a highly liquid capital structure, as evidenced by a current ratio of 16.17 and cash and equivalents of TWD 112.3 million, which significantly exceeds its liabilities of TWD 16.3 million. The company’s debt-to-equity ratio is 0.01, indicating minimal leverage and a conservative financing approach. However, negative operating cash flow of TWD -115.9 million and free cash flow of TWD -104.9 million suggest ongoing operational cash burn. Profitability metrics are negative, with a return on equity of -45.35% and return on assets of -42.7%, reflecting substantial losses relative to equity and asset base. These figures fall well below the industry median for biotechnology firms, which typically require high R&D investment but aim for positive returns by mid-stage development. The company’s revenue is reported as TWD 0.0, indicating no commercial product sales to date. All products remain in development or regulatory review, with no geographic revenue breakdown disclosed. This suggests a high concentration of risk in the success of its pipeline candidates. Growth trajectory is speculative, as the company has not yet generated revenue and is incurring losses. Outlook data is not available for the current or next fiscal year, but the absence of revenue and ongoing cash burn implies a need for continued capital infusions to advance its pipeline. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company’s reliance on R&D and lack of revenue expose it to clinical trial failure, regulatory delays, and competitive pressures. No dilution is currently expected, but the absence of revenue and ongoing losses could necessitate future equity raises. Recent filings and transcripts highlight the company’s focus on advancing MPB-1514 and MPB-1734 through clinical trials, with no material events disclosed in the last quarter. No earnings calls or investor updates were identified in the latest reporting period.